KR102805503B1 - Creb 결합 단백질(cbp)의 저해 - Google Patents

Creb 결합 단백질(cbp)의 저해 Download PDF

Info

Publication number
KR102805503B1
KR102805503B1 KR1020217002866A KR20217002866A KR102805503B1 KR 102805503 B1 KR102805503 B1 KR 102805503B1 KR 1020217002866 A KR1020217002866 A KR 1020217002866A KR 20217002866 A KR20217002866 A KR 20217002866A KR 102805503 B1 KR102805503 B1 KR 102805503B1
Authority
KR
South Korea
Prior art keywords
alkyl
methyl
compound
cycloalkyl
aryl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217002866A
Other languages
English (en)
Korean (ko)
Other versions
KR20210025631A (ko
Inventor
숀 이. 알. 실러
토스텐 허버츠
홍빈 리
브래드포드 그레이브스
스티븐 미쉬키
안젤라 브이. 웨스트
안나 에릭슨
제니퍼 알. 다우닝
Original Assignee
포르마 세라퓨틱스 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from PCT/US2018/051235 external-priority patent/WO2019055877A1/en
Application filed by 포르마 세라퓨틱스 인크. filed Critical 포르마 세라퓨틱스 인크.
Priority to KR1020257014745A priority Critical patent/KR20250067962A/ko
Publication of KR20210025631A publication Critical patent/KR20210025631A/ko
Application granted granted Critical
Publication of KR102805503B1 publication Critical patent/KR102805503B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4738—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4745—Quinolines; Isoquinolines ortho- or peri-condensed with heterocyclic ring systems condensed with ring systems having nitrogen as a ring hetero atom, e.g. phenantrolines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
KR1020217002866A 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해 Active KR102805503B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020257014745A KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Applications Claiming Priority (9)

Application Number Priority Date Filing Date Title
US201862692593P 2018-06-29 2018-06-29
US62/692,593 2018-06-29
USPCT/US2018/051235 2018-09-14
PCT/US2018/051235 WO2019055877A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
PCT/US2018/051214 WO2019055869A1 (en) 2017-09-15 2018-09-14 TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300
USPCT/US2018/051214 2018-09-14
US201962819490P 2019-03-15 2019-03-15
US62/819,490 2019-03-15
PCT/US2019/039936 WO2020006483A1 (en) 2018-06-29 2019-06-28 Inhibiting creb binding protein (cbp)

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020257014745A Division KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Publications (2)

Publication Number Publication Date
KR20210025631A KR20210025631A (ko) 2021-03-09
KR102805503B1 true KR102805503B1 (ko) 2025-05-09

Family

ID=68987627

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020217002866A Active KR102805503B1 (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해
KR1020257014745A Pending KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020257014745A Pending KR20250067962A (ko) 2018-06-29 2019-06-28 Creb 결합 단백질(cbp)의 저해

Country Status (26)

Country Link
US (3) US10870648B2 (https=)
EP (1) EP3998266A1 (https=)
JP (4) JP6781806B2 (https=)
KR (2) KR102805503B1 (https=)
CN (2) CN116178369A (https=)
AU (3) AU2019295790B2 (https=)
BR (1) BR112020026783A2 (https=)
CA (1) CA3105099A1 (https=)
CY (1) CY1124762T1 (https=)
DK (1) DK3587418T3 (https=)
ES (1) ES2900105T3 (https=)
HR (1) HRP20211698T1 (https=)
HU (1) HUE056885T2 (https=)
IL (3) IL279734B2 (https=)
LT (1) LT3587418T (https=)
MA (1) MA50675B1 (https=)
MX (2) MX2023013508A (https=)
PL (1) PL3587418T3 (https=)
PT (1) PT3587418T (https=)
RS (1) RS62732B1 (https=)
SA (1) SA520420909B1 (https=)
SG (1) SG11202012767UA (https=)
SI (1) SI3587418T1 (https=)
SM (1) SMT202100636T1 (https=)
WO (1) WO2020006483A1 (https=)
ZA (2) ZA202100509B (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US10870648B2 (en) * 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)
EP3938365A4 (en) * 2019-03-15 2023-01-25 Forma Therapeutics, Inc. COMPOSITIONS AND METHODS OF TREATMENT OF ANDROGEN RECEPTOR POSITIVE FORMS OF CANCER
WO2020190791A1 (en) 2019-03-15 2020-09-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (creb)
KR20230028798A (ko) 2020-06-25 2023-03-02 톨레모 테라퓨틱스 아게 암 치료를 위한 CBP/p300 브로모도메인 억제제 및 KRAS 억제제의 조합물
BR112022025911A2 (pt) 2020-06-25 2023-01-10 Tolremo Therapeutics Ag Combinação de um inibidor de bromodomínio de cbp/p300 e um inibidor de egfr para uso no tratamento de um cpcnp com egfr mutante
US11801243B2 (en) 2020-09-23 2023-10-31 Forma Therapeutics, Inc. Bromodomain inhibitors for androgen receptor-driven cancers
US11795168B2 (en) * 2020-09-23 2023-10-24 Forma Therapeutics, Inc. Inhibiting cyclic amp-responsive element-binding protein (CREB) binding protein (CBP)

Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2019055869A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Family Cites Families (64)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4404207A (en) 1981-11-06 1983-09-13 Riker Laboratories, Inc. Antimicrobial 8-substituted benzo [IJ]quinolizines
US5138089A (en) * 1986-06-27 1992-08-11 The Procter & Gamble Company Chromophores, sunscreen compositions and methods for preventing sunburn
AU1868195A (en) 1994-01-28 1995-08-15 Cell Therapeutics, Inc. Cell signaling inhibitors
US6011029A (en) 1996-02-26 2000-01-04 Bristol-Myers Squibb Company Inhibitors of farnesyl protein transferase
US6455564B1 (en) 1999-01-06 2002-09-24 Pharmacia & Upjohn Company Method of treating sexual disturbances
US7101869B2 (en) 1999-11-30 2006-09-05 Pfizer Inc. 2,4-diaminopyrimidine compounds useful as immunosuppressants
US7345051B2 (en) 2000-01-31 2008-03-18 Genaera Corporation Mucin synthesis inhibitors
KR100865775B1 (ko) 2000-11-20 2008-10-29 메르크 파텐트 게엠베하 키랄 광이성질성 화합물
WO2003033517A1 (en) 2001-10-17 2003-04-24 The University Of British Columbia Ship 1 modulators
EP1460067A4 (en) 2001-11-26 2005-12-07 Takeda Pharmaceutical BICYCLIC DERIVATIVES, PROCESS FOR THEIR PREPARATION AND THEIR USE
HUP0203976A3 (en) 2002-11-15 2004-08-30 Sanofi Aventis Adenozine a3 receptors, process for their preparation and pharmaceutical compositions containing them
TWI322012B (en) 2002-12-20 2010-03-21 Organon Nv Tetrahydroquinoline derivatives
IN2003CH00929A (https=) 2003-11-13 2008-10-06
WO2005066162A1 (en) 2003-12-23 2005-07-21 Human Biomolecular Research Institute Synthetic compounds and derivatives as modulators of smoking or nicotine ingestion and lung cancer
EP1732541A4 (en) 2004-04-07 2008-03-05 Takeda Pharmaceutical CYCLIC COMPOUNDS
US20060106020A1 (en) 2004-04-28 2006-05-18 Rodgers James D Tetracyclic inhibitors of Janus kinases
US20080318989A1 (en) 2005-12-19 2008-12-25 Burdick Daniel J Pyrimidine Kinase Inhibitors
US20070203236A1 (en) 2006-01-11 2007-08-30 Smith Jeffrey W Novel antagonists of the human fatty acid synthase thioesterase
US20080075692A1 (en) 2006-05-09 2008-03-27 Perrine Susan P Methods for treating blood disorders
EP1878724A1 (en) 2006-07-15 2008-01-16 sanofi-aventis A regioselective palladium catalyzed synthesis of benzimidazoles and azabenzimidazoles
CA2574531C (en) 2007-01-19 2016-10-25 The University Of British Columbia Hat acetylation promoters and uses of compositions thereof in promoting immunogenicity
US8476458B2 (en) 2007-06-21 2013-07-02 The Wistar Institute Methods and compositions for modulating P300/CBP activity
WO2009000413A1 (en) 2007-06-26 2008-12-31 Sanofi-Aventis A regioselective copper catalyzed synthesis of benzimidazoles and azabenzimidazoles
US8222417B2 (en) 2007-06-27 2012-07-17 Taisho Pharmaceutical Co., Ltd Compound having 11β-HSD1 inhibitory activity
TW200930369A (en) 2007-11-15 2009-07-16 Astrazeneca Ab Bis-(sulfonylamino) derivatives in therapy
AR072008A1 (es) 2008-06-13 2010-07-28 Merck & Co Inc Compuestos heterobiciclicos como agentes de inhibicion de quinasa p38
MX2010014066A (es) 2008-06-16 2011-06-01 Univ Tennessee Res Foundation Compuestos para el tratamiento del cancer.
WO2010110380A1 (ja) * 2009-03-27 2010-09-30 興和株式会社 縮合ピペリジン化合物及びこれを含有する医薬
WO2010118208A1 (en) 2009-04-09 2010-10-14 Exelixis, Inc. Benzoxazepin-4- (5h) -yl derivatives and their use to treat cancer
CA2758904C (en) 2009-04-15 2017-04-04 Jw Pharmaceutical Corporation Novel compounds of reverse-turn mimetics, method for manufacturing the same and use thereof
WO2010138490A1 (en) 2009-05-26 2010-12-02 Exelixis, Inc. Benzoxazepines as inhibitors of mtor and methods of their use and manufacture
CN102459248A (zh) 2009-05-26 2012-05-16 埃克塞里艾克西斯公司 作为PI3K/mTOR抑制剂的苯并氧杂环庚三烯以及它们使用与制造方法
US9005670B2 (en) 2010-01-05 2015-04-14 The Johns Hopkins University Use of histone acetyltransferase inhibitors as novel anti-cancer therapies
JP5879273B2 (ja) 2010-03-01 2016-03-08 ジーティーエックス・インコーポレイテッド 癌を処置するための化合物
US8906943B2 (en) 2010-08-05 2014-12-09 John R. Cashman Synthetic compounds and methods to decrease nicotine self-administration
WO2012080729A2 (en) 2010-12-14 2012-06-21 Electrophoretics Limited CASEIN KINASE 1δ (CK1δ) INHIBITORS
US8765978B2 (en) 2010-12-16 2014-07-01 Transitions Optical, Inc. Method of making indeno-fused naphthol materials
EP2678050B1 (en) 2011-02-24 2020-10-14 Emory University Noggin blocking compositions for ossification and methods related thereto
UY34171A (es) 2011-07-01 2013-01-31 Gilead Sciences Inc Compuestos heterocíclicos fusionados como moduladores del canal iónico
GB201111705D0 (en) 2011-07-07 2011-08-24 Takeda Pharmaceutical Compounds and their use
WO2013148114A1 (en) 2012-03-30 2013-10-03 University Of Florida Research Foundation, Inc. P300/cbp inhibitors and methods of use
US9211333B2 (en) 2012-06-05 2015-12-15 Hong Kong Baptist University Anti-cancer agents synthesized based on miliusane compounds
US9593115B2 (en) 2012-09-21 2017-03-14 Advinus Therapeutics Ltd. Substituted fused tricyclic compounds, compositions, and medicinal applications thereof
RU2543485C2 (ru) 2013-02-26 2015-03-10 Андрей Александрович Иващенко Гетероциклические агонисты рецепторов желчных кислот tgr5, фармацевтическая композиция, способы их получения и применения
TWI527811B (zh) 2013-05-09 2016-04-01 吉李德科學股份有限公司 作爲溴結構域抑制劑的苯並咪唑衍生物
SI3010503T1 (sl) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novi biciklični inhibitorji bromodomene
JP6461118B2 (ja) 2013-06-21 2019-01-30 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． ブロモドメイン阻害剤としての新規の置換された二環式化合物
US9975896B2 (en) 2013-07-25 2018-05-22 Dana-Farber Cancer Institute, Inc. Inhibitors of transcription factors and uses thereof
DE102013215912B3 (de) 2013-08-12 2015-02-26 Fraunhofer-Gesellschaft zur Förderung der angewandten Forschung e.V. Farbneutral beschichteter kupferhaltiger Gegenstand, Verfahren zu dessen Herstellung sowie Verwendung einer entsprechenden farbneutralen Beschichtung
TW201605859A (zh) 2013-11-14 2016-02-16 必治妥美雅史谷比公司 作為酪蛋白激酶１δ／ε抑制劑之新穎經取代之吡唑并－哌
RU2720237C2 (ru) 2013-11-18 2020-04-28 Форма Терапеутикс, Инк. Композиции, содержащие бензопиперазин, в качестве ингибиторов бромодоменов вет
CN110627770A (zh) 2013-11-18 2019-12-31 福马疗法公司 作为bet溴域抑制剂的四氢喹啉组成物
EP3193866A1 (en) 2014-09-19 2017-07-26 Genentech, Inc. Use of cbp/ep300 and bet inhibitors for treatment of cancer
WO2016110821A1 (en) 2015-01-08 2016-07-14 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
WO2016128908A1 (en) 2015-02-12 2016-08-18 Advinus Therapeutics Limited Bicyclic compounds, compositions and medicinal applications thereof
GB201506658D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
GB201506660D0 (en) 2015-04-20 2015-06-03 Cellcentric Ltd Pharmaceutical compounds
WO2017197056A1 (en) 2016-05-10 2017-11-16 C4 Therapeutics, Inc. Bromodomain targeting degronimers for target protein degradation
ES2910787T3 (es) 2016-05-12 2022-05-13 Univ Michigan Regents Inhibidores de ASH1L y métodos de tratamiento con los mismos
EP3464270B1 (en) 2016-05-24 2022-02-23 Genentech, Inc. Heterocyclic inhibitors of cbp/ep300 and their use in the treatment of cancer
GB201617630D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
GB201617627D0 (en) 2016-10-18 2016-11-30 Cellcentric Ltd Pharmaceutical compounds
WO2018195155A1 (en) * 2017-04-18 2018-10-25 Celgene Quanticel Research, Inc. Therapeutic compounds
US10870648B2 (en) * 2018-06-29 2020-12-22 Forma Therapeutics, Inc. Inhibiting CREB binding protein (CBP)

Patent Citations (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2011150156A2 (en) 2010-05-26 2011-12-01 Sunovion Pharmaceuticals Inc. Heteroaryl compounds and methods of use thereof
WO2016086200A1 (en) 2014-11-27 2016-06-02 Genentech, Inc. 4,5,6,7-tetrahydro-1 h-pyrazolo[4,3-c]pyridin-3-amine compounds as cbp and/or ep300 inhibitors
WO2019055869A1 (en) 2017-09-15 2019-03-21 Forma Therapeutics, Inc. TETRAHYDROIMIDAZO QUINOLINE COMPOSITIONS AS INHIBITORS OF CBP / P300

Also Published As

Publication number Publication date
MA50675B1 (fr) 2021-09-30
AU2019295790B2 (en) 2023-07-13
BR112020026783A2 (pt) 2021-03-30
US12378242B2 (en) 2025-08-05
AU2019295790A1 (en) 2021-01-28
KR20250067962A (ko) 2025-05-15
US20200002332A1 (en) 2020-01-02
AU2023226653A1 (en) 2023-09-21
IL313466B2 (en) 2025-11-01
KR20210025631A (ko) 2021-03-09
IL313466A (en) 2024-08-01
MA50675A (fr) 2021-04-07
HRP20211698T1 (hr) 2022-02-18
CY1124762T1 (el) 2022-07-22
ZA202100509B (en) 2022-12-21
HUE056885T2 (hu) 2022-03-28
JP6781806B2 (ja) 2020-11-04
JP2020128426A (ja) 2020-08-27
MX2023013508A (es) 2023-12-13
LT3587418T (lt) 2021-11-25
SA520420909B1 (ar) 2024-11-12
US20220162207A1 (en) 2022-05-26
CN112513038B (zh) 2023-01-10
WO2020006483A1 (en) 2020-01-02
JP7017801B2 (ja) 2022-02-09
RS62732B1 (sr) 2022-01-31
SMT202100636T1 (it) 2022-01-10
DK3587418T3 (da) 2021-10-11
JP2025094157A (ja) 2025-06-24
CA3105099A1 (en) 2020-01-02
US10870648B2 (en) 2020-12-22
AU2025210762A1 (en) 2025-08-21
JP2020002135A (ja) 2020-01-09
ES2900105T3 (es) 2022-03-15
PT3587418T (pt) 2021-12-02
US11254674B2 (en) 2022-02-22
PL3587418T3 (pl) 2022-02-21
SI3587418T1 (sl) 2022-03-31
JP2021042255A (ja) 2021-03-18
CN112513038A (zh) 2021-03-16
IL321337A (en) 2025-08-01
MX2020014303A (es) 2021-03-25
SG11202012767UA (en) 2021-01-28
CN116178369A (zh) 2023-05-30
EP3998266A1 (en) 2022-05-18
ZA202210560B (en) 2025-12-17
IL279734B2 (en) 2024-11-01
IL313466B1 (en) 2025-07-01
US20200299295A1 (en) 2020-09-24
IL279734B1 (en) 2024-07-01
AU2023226653B2 (en) 2025-09-04
IL279734A (en) 2021-03-01

Similar Documents

Publication Publication Date Title
KR102805503B1 (ko) Creb 결합 단백질(cbp)의 저해
TWI795440B (zh) 作為ＣＢＰ／ｐ３００抑制劑之四氫─咪唑並喹啉化合物
WO2018024188A1 (zh) 多环化合物、其制备方法、药物组合物及应用
US20250304583A1 (en) Inhibiting g cyclic amp-responsive element-binding protein (creb) binding protein (cbp)
CN112823037A (zh) 抑制去泛素化酶usp25和usp28
EP3587418B1 (en) Inhibitors of creb binding protein (cbp)
HK40074924A (en) Inhibiting creb binding protein (cbp)
EP3937940A1 (en) Inhibiting cyclic amp-responsive element-binding protein (creb)
RU2803290C2 (ru) Ингибирование creb-связывающего белка (cbp)
HK40018316A (en) Inhibitors of creb binding protein (cbp)
HK40018316B (en) Inhibitors of creb binding protein (cbp)
CN113874017A (zh) 抑制环amp-应答元件结合蛋白(creb)
MD3587418T2 (ro) Inhibitori ai proteinei de legare CREB (CBP)
EA046876B1 (ru) Ингибирование creb-связывающего белка (cbp)
BR122025003836A2 (pt) Composto e composição farmacêutica
EA042920B1 (ru) Ингибирование creb-связывающего белка (cbp)

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210127

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220627

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20240610

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250205

PG1601 Publication of registration